Physician profile
David A Tessler
NPI 1659359883
$190,962.76
in general payments reported to CMS, 2019-2025
64 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $5,983 · 2021: $21K · 2022: $42K · 2023: $44K · 2024: $32K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Food and Beverage: $15K · Consulting Fee: $12K · Travel and Lodging: $4,844 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,500.00 |
| Food and Beverage | $14,836.68 |
| Consulting Fee | $12,237.50 |
| Travel and Lodging | $4,844.42 |
| Education | $123.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141,862.34 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| E.R. Squibb & Sons, L.L.C. | $22,387.66 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $4,156.75 | 2020-2022 | |
| Celltrion USA INC. | $3,272.53 | 2024-2025 | Vegzelma |
| Gilead Sciences, INC. | $2,053.49 | 2019-2025 | |
| Ardelyx, INC. | $1,899.58 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,794.03 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Olympus Medical Systems Corporation | $1,787.50 | 2025 | Evis Exera III Duodenovideoscope |
| Celgene Corporation | $1,324.07 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $1,115.86 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $1,115.65 | 2019-2025 | |
| Madrigal Pharmaceuticals | $1,001.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $763.37 | 2023-2025 | |
| Lilly USA, LLC | $568.24 | 2019-2025 | Omvoh, Zepbound, Mounjaro |
| Regeneron Healthcare Solutions, INC. | $542.98 | 2021-2025 | Dupixent |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $541.81 | 2021-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $518.90 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $444.55 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $435.15 | 2024-2025 | Zenpep |
| Allergan, INC. | $354.71 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $322.80 | 2019-2025 | Rebyota, Clenpiq |
| Intercept Pharmaceuticals, INC. | $273.34 | 2019-2025 | |
| Boston Scientific Corporation | $240.73 | 2021-2025 | General - Therapies, Compliance Endokit |
| Lucid Diagnostics INC. | $215.06 | 2023-2024 | |
| Medtronic, INC. | $180.36 | 2021-2023 | Interstim |
| Shionogi INC | $169.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.48 | 2019-2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $137.67 | 2019-2022 | |
| United Therapeutics Corporation | $120.96 | 2021-2025 | Tyvaso, Tyvaso |
| Intuitive Surgical, INC. | $116.77 | 2025 | |
| Amgen INC. | $97.55 | 2020-2025 | Repatha, Otezla, Uplizna |
| Ipsen Biopharmaceuticals, INC | $90.47 | 2025 | Iqirvo |
| Qol Medical, LLC | $79.90 | 2024-2025 | Sucraid, Sucraid |
| Advanced Respiratory, INC | $75.29 | 2020-2021 | |
| Redhill Biopharma INC. | $55.23 | 2020-2021 | |
| Abbott Laboratories | $54.18 | 2023 | Proclaim, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $47.20 | 2022-2024 | Zerbaxa, Dificid, Recarbrio |
| Novartis Pharmaceuticals Corporation | $41.01 | 2020-2023 | |
| Alfasigma USA, INC. | $39.87 | 2020 | |
| Baxter Healthcare | $39.81 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Novo Nordisk INC | $35.13 | 2019-2025 | Wegovy |
| Covis Pharma Gmbh | $30.80 | 2022 | |
| Fresenius Kabi USA, LLC | $30.52 | 2023 | |
| Impulse Dynamics (USA) INC. | $29.79 | 2022-2023 | Optimizer |
| Mallinckrodt Hospital Products INC. | $26.05 | 2022 | |
| Mylan Institutional INC. | $24.85 | 2023 | Hulio |
| Verona Pharma, INC. | $23.07 | 2025 | Ohtuvayre |
| Biocon Biologics INC | $22.98 | 2024 | Hulio |
| Theratechnologies INC. | $21.41 | 2023 | Trogarzo, Egrifta |
| Grifols USA, LLC | $18.71 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.00 | 2023 | Opsumit |
| Hologic Sales and Service, LLC | $17.39 | 2023 | Aptima |
| Organon LLC | $17.21 | 2023 | Renflexis, Hadlima |
| Exact Sciences Corporation | $14.16 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $14.12 | 2021 | |
| Shire North American Group INC | $14.11 | 2019 | |
| Axonics, INC. | $14.03 | 2021 | |
| Ethicon US, LLC | $12.73 | 2020 | |
| Glaxosmithkline, LLC. | $12.71 | 2021 | |
| Covidien LP | $12.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.14 | 2019 | |
| Braintree Laboratories, INC. | $12.11 | 2022 | |
| Ucb, INC. | $11.84 | 2019 | |
| Sanofi Pasteur INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.